Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,123.52 +4,074.67 (+6.90%) CMC Crypto 200
1,363.90 +86.92 (+6.81%)
Halozyme Therapeutics, Inc. (HALO)
After hours:
| Previous close | 39.82 |
| Open | 40.67 |
| Bid | 39.83 x 100 |
| Ask | 46.06 x 100 |
| Day's range | 39.79 - 40.74 |
| 52-week range | 29.85 - 45.00 |
| Volume | |
| Avg. volume | 1,002,227 |
| Market cap | 5.071B |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | 19.00 |
| EPS (TTM) | 2.10 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 51.11 |
Insider MonkeyHow Novo-Catalent Deal Affects Halozyme (HALO)?
Laughing Water Capital, an investment management company, released its first-quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, investment in the fund returned 8.4% after all fees and expenses compared to 10.6% and 5.2% returns for the SP500TR and R2000 during the quarter, respectively. In addition, you […]
ZacksHalozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireMahesh Krishnan Elected to Halozyme's Board of Directors
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
